Jubilant Pharmova's Oral Remdesivir Clears Early Human Trials

Introduction to a Key Development

Jubilant Pharmova Limited has announced a significant step forward in COVID-19 treatment accessibility. Its subsidiary, Jubilant Pharma, successfully completed safety and pharmacokinetic studies for a novel oral formulation of Remdesivir. The studies, conducted on animals and healthy human volunteers in India, compared the new oral version against the commercially available injectable form of the antiviral drug. Following these positive initial results, the company has formally sought authorization from the Drug Controller General of India (DCGI) to proceed with additional, more extensive studies.

The Significance of an Oral Formulation

The development of a viable oral Remdesivir could fundamentally change how COVID-19 is treated. Currently, Remdesivir, a drug fully approved by the US FDA for hospitalized patients, must be administered intravenously. This requirement limits its use to clinical settings, creating logistical challenges and placing a burden on healthcare infrastructure. An oral medication would allow for easier administration, potentially enabling earlier treatment for patients outside of hospitals. This could reduce hospital stays, ease capacity constraints on healthcare facilities, and ensure broader, more timely availability of the treatment, especially during surges in infection rates.

Overcoming a Major Scientific Hurdle

Creating an oral version of Remdesivir has been a longstanding challenge for scientists. The primary obstacle is the drug's interaction with the liver. When administered via a traditional oral route, Remdesivir undergoes what is known as hepatic metabolism, or first-pass clearance. This process causes the liver to break down and eliminate almost the entire dose of the drug before it can enter the bloodstream and take effect. Jubilant's new formulation is specifically designed to bypass this metabolic process, allowing the drug to be absorbed effectively when taken orally. The initial human studies confirmed that the formulation achieves this, showing successful absorption with a safety profile comparable to the injectable version.

Positive Initial Study Outcomes

The preclinical and human volunteer studies yielded promising results. According to the company, the novel oral formulation was well-tolerated by all subjects. Crucially, there were no new or additional safety or tolerability issues identified when compared to the established profile of the injectable Remdesivir. The findings confirmed that the drug is absorbed into the body when administered through this new oral method. Confident in these results, Jubilant is now preparing for the next phase of clinical development, pending approval from the DCGI. The proposed treatment course for the oral version is five days, mirroring the duration of the injectable form.

Strategic Partnership with Gilead Sciences

This development builds on a pre-existing strategic relationship. In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, the original developer of Remdesivir. This agreement granted Jubilant the right to manufacture, register, and sell the antiviral drug in 127 countries, including India. Subsequently, in July 2020, Jubilant received DCGI approval to produce and market the injectable form of Remdesivir under the brand name 'JUBI-R' for restricted emergency use in India for severe COVID-19 cases. The move to develop an oral formulation represents a logical and innovative extension of this partnership.

Company Financials and Market Position

Jubilant Pharmova, incorporated in 1978, is a significant player in the Indian pharmaceutical sector. The company's financial health and strategic initiatives have been recognized by rating agencies, with Fitch upgrading its rating from BB- to BB in 2021, citing an improved business profile. The company's focus on high-growth areas like Contract Development and Manufacturing Organisation (CDMO) and generics has driven strong financial performance, including a 52% year-on-year growth in the third quarter of 2020.

Broader Business Operations

Formerly known as Jubilant Life Sciences, the company rebranded to Jubilant Pharmova Limited in February 2021 after demerging its Life Science Ingredients (LSI) business. This strategic move created two distinct entities, allowing the pharmaceutical business to focus on its core segments. The company operates across Radiopharma, Allergy Immunotherapy, Sterile Injectables (CDMO), Generics, Contract Research (CRDMO), and Proprietary Novel Drugs, serving a diverse client base that includes pharmaceutical companies, biotech firms, and hospitals globally.

Future Outlook and Market Impact

The successful development and approval of an oral Remdesivir formulation would be a major catalyst for Jubilant Pharmova. It would not only provide a more convenient treatment option for a global health crisis but also position the company as an innovator in drug delivery. Pramod Yadav, CEO of Jubilant Pharma, stated that the formulation would support the increasing demand for COVID-19 treatments. Analysts have maintained a 'Buy' rating on the stock for the long term, and this development could further bolster investor confidence. The next critical milestone is the decision from the DCGI, which will determine the timeline for the subsequent phases of clinical trials and eventual market launch.